Xenetic Biosciences, Inc.
XBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | 0.03 | 0.04 | 0.03 |
| FCF Yield | -45.81% | -78.03% | -126.96% | -35.73% |
| EV / EBITDA | 0.00 | 0.82 | 1.35 | 0.87 |
| Quality | ||||
| ROIC | -69.99% | -46.10% | -49.23% | -31.20% |
| Gross Margin | 100.00% | 100.00% | 98.42% | 96.94% |
| Cash Conversion Ratio | 0.71 | 1.00 | 0.71 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.57% | 29.83% | 57.49% | 308.19% |
| Free Cash Flow Growth | 31.52% | 20.06% | -8.63% | -11.03% |
| Safety | ||||
| Net Debt / EBITDA | 1.52 | 1.99 | 1.96 | 3.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -3,878.50 | -3,728.69 |